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Abstract
Background: Venous thromboembolism (VTE) is a common complication during and after a hospital admission.
Although it is mainly considered a complication of surgery, it often occurs in people who have not undergone
surgery, with recent evidence suggesting that immune-mediated diseases may play a role in VTE risk. We,
therefore, decided to study the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in people
admitted to hospital with a range of immune-mediated diseases.
Methods: We analysed databases of linked statistical records of hospital admissions and death certificates for the
Oxford Record Linkage Study area (ORLS1:1968 to 1998 and ORLS2:1999 to 2008) and the whole of England (1999
to 2008). Rate ratios for VTE were determined, comparing immune-mediated disease cohorts with comparison
cohorts.
Results: Significantly elevated risks of VTE were found, in all three populations studied, in people with a hospital
record of admission for autoimmune haemolytic anaemia, chronic active hepatitis, dermatomyositis/polymyositis,
type 1 diabetes mellitus, multiple sclerosis, myasthenia gravis, myxoedema, pemphigus/pemphigoid, polyarteritis
nodosa, psoriasis, rheumatoid arthritis, Sjogren’s syndrome, and systemic lupus erythematosus. Rate ratios were
considerably higher for some of these diseases than others: for example, for systemic lupus erythematosus the rate
ratios were 3.61 (2.36 to 5.31) in the ORLS1 population, 4.60 (3.19 to 6.43) in ORLS2 and 3.71 (3.43 to 4.02) in the
England dataset.
Conclusions: People admitted to hospital with immune-mediated diseases may be at an increased risk of
subsequent VTE. Our findings need independent confirmation or refutation; but, if confirmed, there may be a role
for thromboprophylaxis in some patients with these diseases.
Introduction
Venous thromboembolism (VTE), which comprises deep
vein thrombosis (DVT) and pulmonary embolism (PE),
is thought to account for an estimated 25,000 deaths
annually in the UK [1], with a recent study suggesting
that the figure might be as high as 60,000 [2]. VTE is a
common complication during and after hospitalisation
for acute medical illness or surgery [3]. PE accounts for
5 to 10% of deaths in hospitalised patients, making VTE
the most common preventable cause of in-hospital
death [3]. Risk factors for VTE include immobility, age
and obesity [1].
Although VTE has traditionally been considered a sur-
gical condition, the vast majority of hospitalised patients
with symptomatic VTE have not undergone recent sur-
gery [4]. Indeed, up to 80% of in-hospital fatal PEs
occur in nonsurgical patients [4]. Patients with inflam-
matory bowel disease [5], rheumatoid arthritis [6], type
1 diabetes [7] and systemic lupus erythematosus (SLE)
[8] are at an increased risk of VTE, suggesting that
there may be a more general association between
immune-mediated diseases and VTE.
To investigate this further, we undertook a record
linkage study to determine the risk of VTE in indivi-
duals with selected immune-mediated diseases using the
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long-standing Oxford Record Linkage Study (ORLS) [9]
and the more recent English national linked Hospital
Episode Statistics (HES) dataset.
Methods
Population and data
The Oxford Record Linkage Study (ORLS) [9] includes
brief statistical abstracts of records of all hospital admis-
sions (including day cases) in National Health Service
(NHS) hospitals, and all deaths regardless of where they
occurred, in defined populations within the former
Oxford NHS Region. The original ORLS covered the
years 1963 to 1998, and is referred to here as ORLS1.
The hospital data were collected routinely in the NHS
as the region’s hospital statistics system and were similar
to English national hospital episode statistics (HES). A
second dataset, referred to as ORLS2, has been linked
and built as the Oxford regional subset of the English
national Hospital Episode Statistics (HES), and runs
from 1999 to 2008. The data items available for linkage
changed between 1998 and 1999 and the two datasets
are not themselves linked together. We have also used
the complete dataset of the English national HES (1999
to 2008). Death data in each of the three datasets derive
from death certificates. The population covered by
ORLS1 gradually expanded over time from an initial
population of part of Oxfordshire (an approximately
300,000 resident population) to all four counties of the
former Oxford NHS region (resident population 2.5 mil-
lion); and the ORLS2 covers the same four counties.
The population of England is 50 million. The datasets
used in this study (versions m6v2 for ORLS and v08a
for ORLS2 and England) have been constructed by staff
in the Oxford Unit of Healthcare-Epidemiology.
The basic methods were the same for the analysis of
each disease and are described for rheumatoid arthritis
and VTE. A cohort of people with a record of admission
or day case care for rheumatoid arthritis was con-
structed for those with a principal diagnosis of rheuma-
toid arthritis, as the reason for hospital care, by
identifying the first admission, or episode of day case
care, for the condition in an NHS hospital during the
study period of 1963 to 1998 in ORLS1, 1999 to 2008 in
ORLS2, and 1999 to 2008 for the whole of England. The
International Classification of Disease (ICD) codes used
for each immune-mediated disease can be found in
Table 1 and 2. The ICD codes used for VTE (DVT and
PE) were: 465 in ICD 7; 450 in ICD8; 415.1, 451.1 and
453.9 in ICD9; I26 and I80.2 in ICD10. A reference
cohort was constructed by identifying the first admission
Table 1 Number of people in the study with each immune-mediated disease, and percentage of females
Exposure cohort (and ICD code1) ORLS1 ORLS2 England
Total (% female) Total (% female) Total (% female)
Addison’s disease (255.4) 489 (64) 624 (60) 10,257 (60)
Ankylosing spondylitis (720) 976 (30) 991 (29) 2,2001 (29)
Autoimmune haemolytic anaemia (283) 421 (55) 377 (59) 7,854 (55)
Chronic active hepatitis (571.4) 431 (61) 209 (71) 4512 (70)
Coeliac disease (579.0) 1,722 (61) 2,324 (66) 48,239 (66)
Dermatomyositis, polymyositis (710.3,710.4) 328 (63) 268 (70) 6,002 (63)
Diabetes mellitus under 30 (250) 4,950 (47) 4,410 (48) 79,581 (48)
Goodpasture’s syndrome (446.2) 76 (53) 53 (43) 999 (45)
Hashimoto’s thyroiditis (245) 524 (87) 384 (90) 8,573 (88)
Idiopathic thrombocytopenia purpura (287.3) 779 (54) 1,221 (57) 25,984 (55)
Multiple sclerosis (340) 3,823 (66) 4,106 (68) 81,950 (68)
Myasthenia gravis (358) 379 (63) 420 (57) 10,024 (51)
Myxoedema (244) 6,738 (82) 23,456 (81) 63,0354 (81)
Pemphigus, pemphigoid (694.4,694.5) 537 (57) 492 (57) 11,480 (57)
Pernicious anaemia (281) 4,131 (63) 1,457 (70) 47,092 (68)
Polyarteritis nodosa (446) 298 (42) 84 (42) 2,088 (43)
Primary biliary cirrhosis (571.6) 359 (77) 367 (83) 9,060 (85)
Psoriasis (696.0,696.1,696.8,696.9) 3,910 (52) 3,365 (48) 85,358 (48)
Rheumatoid arthritis (714) 14,231 (73) 11,241 (72) 268,005 (71)
Scleroderma (710.1) 363 (80) 542 (85) 11,643 (82)
Sjogren’s syndrome (710.2) 165 (86) 446 (89) 12,680 (89)
Systemic lupus erythematosus (710.0) 594 (86) 997 (87) 23,544 (87)
Thyrotoxicosis (242) 5,503 (81) 3,986 (89) 91,913 (79)
1 ICD 9 codes for each disease (equivalent codes were used for cases coded in ICD Revisions 7, 8 and 10)
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for each individual with various other, mainly minor
medical and surgical, conditions (listed in Table 2 foot-
notes). This is based on a ‘reference’ group of conditions
that has been used in other studies of associations
between diseases [10-12]. In its design, the standard epi-
demiological practice was followed, when hospital con-
trols are used, of selecting a diverse range of conditions,
rather than relying on a narrow range (in case the latter
are themselves atypical in their risk of subsequent dis-
ease). As a check, we have studied the risk of VTE in
the control conditions within the reference cohort to
ensure that the reference cohort does not include con-
trol conditions that have atypically high or low VTE
rates.
People were included in the rheumatoid arthritis or
reference cohort if they did not have an admission for
VTE either before or at the same time as the admission
for rheumatoid arthritis or the reference condition. We
then searched the database for any subsequent NHS
hospital care for, or death from, VTE in these cohorts.
We considered that rates of VTE in the reference cohort
would approximate those in the general population of
the region while allowing for migration in and out of it
(data on migration of individuals were not available).
Statistical methods
We calculated rates of VTE based on cohort analysis.
For each broad age group of people with rheumatoid
arthritis, and for VTE, we took “date of entry” into each
cohort as the date of first admission for rheumatoid
arthritis, or reference condition, and “date of exit” as the
date of first record of VTE, death, or the end of the
data file (31 December 1998 for ORLS1; 31 March 2008
for ORLS2 and English HES), whichever was the earliest.
Table 2 Rate ratios1 and 95% confidence intervals (CIs) for venous thromboembolism, compared with the control
cohort2
Dataset (years)
Immune-mediated disease (ICD code3) ORLS1 (1963 to 1998) Rate
ratio (95% CI) P-value
ORLS2 (1999 to 2008) Rate
ratio (95% CI) P-value
England (1999 to 2008) Rate
ratio (95% CI) P-value
Addison’s disease (255.4) 1.49 (0.79 to 2.55) 0.20 2.96 (1.53 to 5.20) < 0.001 2.15 (1.86 to 2.47) < 0.001
Ankylosing spondylitis (720) 1.35 (0.80 to 2.13) 0.26 1.18 (0.56 to 2.17) 0.73 1.93 (1.74 to 2.14) < 0.001
Autoimmune haemolytic anaemia (283) 2.83 (1.62 to 4.60) <0.001 3.64 (2.11 to 5.85) <0.001 3.83 (3.43 to 4.25) < 0.001
Chronic active hepatitis (571.4) 2.24 (1.25 to 3.70) 0.003 3.99 (1.46 to 8.72) 0.001 2.04 (1.65 to 2.50) <0.001
Coeliac disease (579.0) 1.35 (0.89 to 1.97) 0.21 1.36 (0.87 to 2.03) 0.17 1.21 (1.11 to 1.33) <0.001
Dermatomyositis, polymyositis (710.3,710.4) 1.98 (0.99 to 3.55) 0.04 2.90 (1.16 to 5.98) 0.009 3.04 (2.60 to 3.54) <0.001
Diabetes mellitus under 30 (250) 2.13 (1.33 to 3.26) 0.001 3.22 (1.79 to 5.54) <0.001 2.58 (2.22 to 2.98) <0.001
Goodpasture’s syndrome (446.2) 2.29 (0.28 to 8.28) 0.50 6.89 (1.87 to 17.7) <0.001 2.78 (1.78 to 4.14) <0.001
Hashimoto’s thyroiditis (245) 0.89 (0.38 to 1.75) 0.87 0.91 (0.19 to 2.67) 0.91 1.41 (1.15 to 1.72) 0.001
Idiopathic thrombocytopenia purpura (287.3) 2.04 (0.93 to 3.88) 0.05 1.58 (0.97 to 2.42) 0.05 2.09 (1.90 to 2.29) <0.001
Multiple sclerosis (340) 2.24 (1.83 to 2.72) <0.001 2.52 (2.00 to 3.13) <0.001 2.14 (2.03 to 2.26) <0.001
Myasthenia gravis (358) 2.04 (1.09 to 3.49) 0.02 2.34 (1.24 to 4.01) 0.003 2.26 (2.00 to 2.54) <0.001
Myxoedema (244) 1.47 (1.27 to 1.70) <0.001 1.36 (1.22 to 1.52) <0.001 1.30 (1.27 to 1.33) <0.001
Pemphigus, pemphigoid (694.4,694.5) 2.69 (1.90 to 3.70) <0.001 3.28 (2.07 to 4.94) < 0.001 2.22 (2.00 to 2.45) <0.001
Pernicious anaemia (281) 1.20 (0.99 to 1.44) 0.06 1.44 (0.97 to 2.07) 0.06 1.36 (1.27 to 1.45) <0.001
Polyarteritis nodosa (446) 2.88 (1.70 to 4.55) <0.001 4.36 (0.90 to 12.8) 0.03 3.53 (2.76 to 4.44) <0.001
Primary biliary cirrhosis (571.6) 1.29 (0.52 to 2.67) 0.64 2.76 (1.37 to 4.95) 0.001 1.49 (1.26 to 1.74) <0.001
Psoriasis (696.0,696.1,696.8,696.9) 1.62 (1.32 to 1.98) <0.001 1.65 (1.23 to 2.17) <0.001 1.66 (1.57 to 1.75) <0.001
Rheumatoid arthritis (714) 1.45 (1.31 to 1.60) <0.001 1.57 (1.37 to 1.79) <0.001 1.75 (1.70 to 1.80) <0.001
Scleroderma (710.1) 2.16 (0.99 to 4.10) 0.03 1.53 (0.70 to 2.91) 0.29 1.97 (1.73 to 2.23) <0.001
Sjogren’s syndrome (710.2) 2.85 (1.37 to 5.25) 0.001 1.91 (1.02 to 3.28) 0.03 2.02 (1.80 to 2.26) <0.001
Systemic lupus erythematosus (710.0) 3.61 (2.36 to 5.31) <0.001 4.60 (3.19 to 6.43) <0.001 3.71 (3.43 to 4.02) <0.001
Thyrotoxicosis (242) 1.14 (0.95 to 1.36) 0.14 1.56 (1.23 to 1.95) <0.001 1.34 (1.27 to 1.42) <0.001
1 Adjusted for sex, age in five-year bands, time-period in single calendar years and district of residence in the ORLS datasets; and for sex, age in five-year bands,
time-period in single calendar years, region of residence and deprivation score associated with patients’ area of residence, in quintiles, in the England dataset.
The rate ratios are calculated as the ratio of the observed/expected number in the cohort for each immune-mediated disease (see Appendix) to the observed/
expected numbers in the reference cohort as calculated in the analysis undertaken for each of the individual disease (data not shown).
2 Conditions used in reference cohort, with Office of Population, Censuses and Surveys (OPCS) code edition 3 for operations and ICD9 code for diagnosis) (with
equivalent codes used for other coding editions): appendicectomy (OPCS3 441), squint (ICD9 378), otitis externa, otitis media (380 to 382), haemorrhoids (455),
deflected septum, nasal polyp (470 to 471), impacted tooth and other disorders of teeth (520 to 521), inguinal hernia (550)), ingrown toenail and other diseases
of nail (703), sebaceous cyst (706.2), internal derangement of knee (717), bunion (727.1), dislocations, sprains and strains (830 to 839, 840 to 848), superficial
injury and contusion (910 to 919, 920 to 924).
3 ICD 9 codes for each immune-mediated disease (equivalent codes were used for cases coded in ICD Revisions 7, 8 and 10.)
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In the ORLS cohorts, in comparing the rheumatoid
arthritis cohort with the reference cohort, we first calcu-
lated rates for VTE, stratified and then standardised by
age (in five-year age groups), sex, calendar year of first
recorded admission, and district of residence, to ensure
that the results of group comparisons were equivalent in
these respects. We used a similar approach to standardi-
sation in the England dataset, stratifying by age (in five-
year age groups), sex, calendar year of first recorded
admission, region of residence, and quintile of patients’
Index of Deprivation score (as a measure of socio-eco-
nomic status). We used the indirect method of standar-
disation, using the combined rheumatoid arthritis and
reference cohorts as the standard population. We
applied the stratum-specific rates in the combined rheu-
matoid arthritis and reference cohorts to the number of
people in each stratum in the rheumatoid arthritis
cohort, separately, and then to those in the reference
cohort. We calculated the ratio of the standardised rate
of occurrence of VTE in the exposure cohorts relative
to that in the reference cohort. The confidence interval
for the rate ratio and c2 statistics for its significance
were calculated as described elsewhere [13]. Calculated
in this way, the rate ratio provides a measure of relative
risk of VTE in the rheumatoid arthritis cohort, com-
pared with the reference cohort. The fact that there is
unmeasured migration in the populations covered by
the study, and the use of an internal reference cohort
for comparison with the VTE rates in the rheumatoid
arthritis cohort (and others), preclude meaningful calcu-
lation of absolute risks.
We analysed the occurrence of an admission for VTE
within 90 days of the admission for each immune-
related disease, and at 91 days and more, to help estab-
lish whether any elevated risk of VTE was confined to
the short-term after the episode of hospitalisation or
was more prolonged.
In the analysis of diabetes mellitus, we used hospital
admission for diabetes mellitus when aged under 30 as a
proxy for type 1 diabetes, as the type of diabetes is not
well recorded in routine hospital statistics. We analysed
the data for males and females separately, as well as
together, to ascertain whether or not there were differ-
ences between them in risk of VTE.
Results
Table 1 shows the number of people in the study who
were admitted to the hospital with each of the selected
immune-mediated diseases; it also shows the percentage
of these who were female. The number of people in
each of the three corresponding comparison cohorts
were: 313,716 (47% female) for ORLS1, 187,609 (46%
female) for ORLS2, and 3,707,315 (41% female) for
England.
There were elevated risks of VTE after hospital admis-
sion for the following individual immune-mediated dis-
eases, in all three of the populations studied: autoimmune
haemolytic anaemia, chronic active hepatitis, dermatomyo-
sitis/polymyositis, type 1 diabetes mellitus, multiple sclero-
sis (MS), myasthenia gravis, myxoedema, pemphigus/
pemphigoid, polyarteritis nodosa, psoriasis, rheumatoid
arthritis, Sjogren’s syndrome, and SLE (Table 2 and
Appendix).
In the much larger population of England, we also found
elevated risks for VTE in people admitted with Addison’s
disease, ankylosing spondylitis, coeliac disease, Goodpas-
ture’s syndrome, Hashimoto’s thyroiditis, idiopathic
thrombocytopenia purpura, pernicious anaemia, primary
biliary cirrhosis, scleroderma and thyrotoxicosis (Table 2).
High levels of risk, substantially higher than the risks
associated with some of the other diseases, were found
for SLE and polyarteritis nodosa. The rate ratios for SLE
were 3.61 (2.36 to 5.31) in the ORLS1 population, 4.60
(3.19 to 6.43) in ORLS2 and 3.71 (3.43 to 4.02) in the
English national dataset. Those for polyarteritis nodosa
were, respectively, 2.88 (1.70 to 4.55), 4.36 (not quite
significant with CIs of 0.90 to 12.8) and 3.53 (2.76 to
4.44). Consistently high levels of risk were also found
for chronic active hepatitis, dermatomyositis and poly-
myositis, diabetes mellitus, MS and Sjogren’s syndrome.
Males and females
On the whole, the rate ratios for males and females
were similar although some of the numbers in ORLS1
and ORLS2 became rather small when subdivided by
sex. In the England dataset, there was a significant ele-
vation of VTE risk in males with coeliac disease (RR
1.47; 1.26 to1.70), but not in females (1.09; 0.97 to 1.23).
Similarly, the VTE rate ratio for males with Hashimoto’s
thyroiditis was significantly elevated (2.98; 1.86 to 4.51),
but the rate ratio in females was not (1.23; 0.97 to 1.54).
There were no other significant differences between
males and females.
Short (0 to 90 days) and long-term (91+ days)
associations with VTE
We studied the occurrence of VTE in time intervals
after admission. However, subdividing the results into 0
to 90 days and 91+ days since immune-mediated disease
admission did reduce power. Only MS, myxoedema,
psoriasis, rheumatoid arthritis and SLE had sufficient
numbers for meaningful analysis. Table 3 shows that, in
general, associations with increased VTE risk were
found for these diseases at both short and long intervals.
Absolute risk
Although we could not calculate meaningful absolute
risks for the ORLS1 and ORLS2 cohorts, because of
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migration into and out of the Oxford region, approxi-
mate absolute risks can be calculated in the English
national data. For example, there were 81,950 people
in the MS cohort of whom 1,509 had an admission for
VTE (1.8%) during the 10-year period covered by the
study. As an approximation, in people with MS there
was one case of VTE per 264 person-years at risk.
Similar calculations show that 2.7% of people with SLE
had an admission for VTE in the period covered by
the study, and that the event rate was one case of VTE
per 169 person-years at risk. These calculations assume
that migration was small and that its effect was
unimportant.
Discussion
The ORLS1 (1963 to 1998) and ORLS2 (1999 to 2008)
cover broadly the same population but at different
times. The English linked dataset is completely indepen-
dent of ORLS1 and it covers a far larger population in
the same timeframe as ORLS2. The results of the ana-
lyses in the three datasets corroborate each other. Pre-
vious studies have found elevated risks of VTE in people
with rheumatoid arthritis [6], type 1 diabetes mellitus
[7], SLE[8] and inflammatory bowel disease [5]. We
have not reported on inflammatory bowel diseases here
as they are included in a different epidemiological study
that we hope to publish separately. These previous find-
ings, combined with our own, suggest that there may be
a general association between immune-mediated dis-
eases and the risk of subsequent VTE. This risk is not
solely associated with the short term after hospital
admission: for the diseases with large enough numbers
to study, it was sustained over time.
The increased risks of VTE may have different underly-
ing causes in each disease. The elevated risks may be a
reflection of patients with more extreme cases of the
immune-mediated diseases, in that the populations in
our study are those admitted to hospital. Immobility [14],
effects of treatment (corticosteroids promote haemosta-
sis) [15] or a true effect of inflammation on coagulation
[16] could all be implicated in the associations shown.
In 1856, Virchow proposed three precipitants for
venous thrombosis: venous stasis, increased coagulability
of the blood, and damage to the vessel wall [17]. Inflam-
mation is a key determinant of endothelial function in
both arteries and veins and results in changes in expres-
sion of selectins and cellular adhesion molecules [16].
Studies have shown that patients with VTE were more
likely to have elevated plasma IL-8, IL-6, MCP-1 and
TNF-a levels [18], that inflammation influences clotting
factor levels [19], that an inflammatory gene is asso-
ciated with VTE [20] and acute inflammation does con-
tribute to VTE [21]. Taken together, inflammation is
likely to contribute to some extent to the initiation of
venous thrombus formation.
Methodological issues: datasets, population, and multiple
comparisons
Strengths of the datasets include their size, with large
numbers of fairly uncommon diseases. The ORLS1 data
provide long duration of follow-up; the English data
provide a much larger and more recent population but
with shorter follow-up. The risk of VTE was therefore
studied for a large number of immune-mediated dis-
eases, all within a single population and using the same
methodology. Accordingly, levels of risk associated with
different immune-mediated diseases can be directly
compared within the same study populations.
Our study should be regarded as exploratory rather
than definitive. We studied a wide range of immune-
mediated diseases with differing aetiologies. We did so
because, as an exploratory study, with very large linked
datasets in which many diseases can be studied, we saw
no reason to be restrictive in our selection of diseases.
Table 3 Occurrence of VTE within 90 days or more than 90 days after admission for immune-mediated disease
Exposure, time between
exposure and VTE (days)
ORLS1 ORLS2 England
Obs Exp RR1 (95% CI) Obs Exp RR1 (95% CI) Obs Exp RR1 (95% CI)
MS 0 to 90 10 8.1 1.25 (0.59 to 2.31) 17 6.7 2.64 (1.51 to 4.33) 212 112 1.95 (1.69 to 2.24)
91+ 96 43.7 2.23 (1.80 to 2.74) 71 30.1 2.45 (1.90 to 3.13) 1297 619 2.17 (2.05 to 2.30)
Myxoedema 0 to 90 38 39.8 0.95 (0.66 to 1.32) 126 95.9 1.48 (1.18 to 1.85) 2617 2058 1.48 (1.41 to 1.56)
91+ 160 107 1.52 (1.29 to 1.79) 305 245 1.32 (1.16 to 1.51) 8487 7237 1.26 (1.22 to 1.29)
Psoriasis 0 to 90 12 11.6 1.04 (0.53 to 1.83) 15 6.5 2.41 (1.33 to 4.06) 226 134 1.73 (1.51 to 1.98)
91+ 87 54.2 1.62 (1.29 to 2.00) 38 26.5 1.45 (1.02 to 2.01) 1092 679 1.64 (1.54 to 1.75)
Rheumatoid arthritis: 0 to 90 52 61.7 0.83 (0.61 to 1.10) 50 37.0 1.43 (1.03 to 1.95) 1122 730 1.71 (1.60 to 1.83)
91+ 395 279.8 1.46 (1.31 to 1.62) 231 156 1.60 (1.38 to 1.85) 5703 3626 1.75 (1.70 to 1.81)
SLE 0 to 90 5 1.4 3.64 (1.18 to 8.56) 6 1.8 3.41 (1.24 to 7.75) 111 27.4 4.15 (3.40 to 5.01)
91+ 21 6.5 3.25 (2.01 to 4.98) 29 5.9 5.03 (3.35 to 7.27) 525 148 3.61 (3.31 to 3.94)
1 Adjusted for sex, age in five-year bands, time-period in single calendar years and district of residence in the ORLS datasets; and for sex, age in five-year bands,
time-period in single calendar years, region of residence and deprivation score associated with patients’ area of residence, in quintiles, in the England dataset.
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The datasets have limitations. The cohorts are based
on prevalent cases, the first recorded hospital admission
or episode of day case care for each person with each
condition, rather than being cohorts with follow-up
from the date of first diagnosis. Data are not recorded
on patients who move out of the area covered by data
collection or who are treated in hospitals outside the
area (mainly affecting ORLS). The datasets are limited
to people who were admitted to hospital, or who
received day case specialist care. This would not capture
all people with each immune-mediated disease, although
it should identify the great majority with subsequent
diagnosed VTE. These factors are part of our reasoning
for including a comparison cohort of patients admitted
to hospital, or in receipt of day case care, from the same
database and for ‘matching’, through stratified analysis,
for area of treatment and for year of first recorded diag-
nosis as well as for age and sex. The two Oxford data-
sets are not linked to each other due to changes in the
data items available for linkage between 1998 and 1999.
Consequently, it is likely that some people have been
recorded as having a ‘first admission’ for each immune-
mediated disease in each of the time periods studied.
We lack clinical and laboratory data. We lack treat-
ment data for the immune-mediated diseases; and ele-
ments of their treatment could themselves influence
VTE risk. There is very limited information on potential
confounding factors such as socioeconomic status, and
none on smoking or ethnicity. As we comment above,
our results should be regarded as speculative rather
than definitive: they represent results from what can be
done using very large-scale, routinely collected adminis-
trative data. They need further work, in different study
designs, to confirm or refute the findings, although epi-
demiological studies involving direct patient contact
may be quite formidable logistical undertakings on the
scale required.
Our rate ratio for VTE in people admitted to hospital
with rheumatoid arthritis in the English dataset was
1.75, which is comparable with a previous study that
reported a relative risk of 1.99 [6]. Our rate ratio for
VTE in people aged under 30 with diabetes was 2.58 in
the English dataset, which compares with a reported fig-
ure of 1.73 in hospitalised patients with diabetes aged
20 to 29 in the USA [7]. Although the literature is
sparse on VTE in people with immune-mediated dis-
eases, our findings seem broadly comparable with find-
ings of others.
We used age at admission under 30 as a proxy for
type 1 diabetes mellitus, as the type of diabetes is not
routinely recorded on hospital admission records.
Although this will mostly consist of people with type 1
diabetes, there may be a few people with type 2 diabetes
in the cohort as well.
We studied a large number of associations between
diseases. The effect of making multiple comparisons
needs to be considered. For this reason, we have given
exact P-values, as well as confidence intervals, so that
the reader can judge the degree of significance of each
immune-mediated disease and subsequent VTE. It is
possible that some of the associations that are significant
at a level of P < 0.05 or P < 0.01 may result from mak-
ing multiple comparisons and the play of chance. This
may particularly be so where there is no prior hypoth-
esis to support the finding. On the other hand, even in
a study with the number of comparisons that we have
made, findings where the significance level is <0.001 or
less, are unlikely to be attributable to chance alone.
There were differences in levels of risk between the dis-
eases studied: for example, the rate ratios for SLE were
significantly and substantially higher than those for
myxoedema. Even if the fairly low levels of elevation of
risk, such as those associated with myxoedema and thyr-
otoxicosis, are considered unimportant, the high levels
of risks associated with SLE, polyarteritis nodosa and
diabetes mellitus are striking. The large numbers of
findings with highly significant results in the England
cohort needs comment. They no doubt in part reflect
the very large numbers of patients in the cohort, such
that many differences are significant, even if fairly small
(for example, coeliac disease, thyroiditis, myxoedema,
thyrotoxicosis), as a result of high statistical power.
Conclusion
This is an exploratory study into the risk of VTE in peo-
ple admitted to hospital with a range of immune-
mediated diseases. Further studies are needed, of indivi-
dual immune-mediated diseases, in greater depth, to
confirm or refute our findings. Given that a large pro-
portion of hospitalised patients are at risk for VTE, and
that there is, generally, a low rate of appropriate prophy-
laxis, our data suggest that patients with selected
immune-mediated disease may need to be considered
for thromboprophylaxis. This may be particularly war-
ranted in people with diseases at relatively high risk of
VTE, such as SLE and polyarteritis nodosa. However,
the risk of VTE for any immune-mediated disease we
studied is at least an order of magnitude lower than the
risk of VTE after surgery[22]. Further investigation is
required, prospectively, to determine the thrombopro-
phylaxis status of patients with these immune-mediated
diseases who experience VTE. If a substantial proportion
of such patients are found not to have been receiving
thromboprophylaxis, current recommendations on
thromboprophylaxis may need to be re-examined, as the
disorders we studied here were not included as risk fac-
tors in the recent NICE guidelines on reducing the risk
of VTE [23]. Prospective studies are needed to
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determine the predictive value of inflammatory markers
for VTE, but this may also aid in the identification of
individuals who strongly warrant preventative therapy.
Appendix
Observed (O) and Expected (E) numbers of people with
an admission for DVT or PE in people with selected
immune-mediated diseases (see Table 4).
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